质子与碳离子治疗脑膜瘤和胶质瘤的现状综述
本文为叙述性综述,总结质子束治疗(PBT)和碳离子放疗(CIRT)治疗脑膜瘤与胶质瘤的现状。PBT治疗脑膜瘤长期局部控制率高、症状恶化率低,或可安全提升剂量;CIRT数据有限但现有系列几乎无高级别毒性且局部控制率高。低级别胶质瘤中PBT可在不增加严重毒性前提下提升剂量,PBT和CIRT也用于胶质母细胞瘤并可能更安全再照射。现有证据多为回顾性、存在选择偏倚和异质性,经济性问题仍待解答。
要点
- PBT治疗脑膜瘤长期局部控制率高、症状恶化率低,特定病例可安全提升剂量。
- CIRT治疗脑膜瘤现有数据有限,几乎无高级别毒性且局部控制率高。
- 低级别胶质瘤PBT可提升剂量且不增加严重毒性,并维持生活质量。
核心结论
- PBT治疗脑膜瘤显示高长期局部控制率和低症状恶化率,并可能安全提升剂量。
- CIRT数据有限,现有系列几乎无高级别毒性且局部控制率高。
- 低级别胶质瘤PBT可在不增加严重毒性下提升剂量并维持生活质量。
- PBT和CIRT用于胶质母细胞瘤,并可能更安全地进行高级别胶质瘤再照射。
- 现有证据数量和质量有限,经济性问题仍存重大疑问。
研究设计与样本
- 叙述性综述,总结质子束治疗和碳离子放疗治疗脑膜瘤与胶质瘤的现状。
- 脑膜瘤和胶质瘤分别是中枢神经系统最常见的良性原发脑肿瘤。
主要发现
- PBT治疗脑膜瘤长期局部控制率高、症状恶化率低,特定病例可安全提升剂量。
- CIRT治疗脑膜瘤现有系列几乎无高级别毒性且局部控制率高。
- 低级别胶质瘤PBT可提升剂量且不增加严重毒性,并维持适当生活质量。
- PBT和CIRT用于胶质母细胞瘤,并可能更安全地进行高级别胶质瘤再照射。
- PBT和CIRT的优越剂量学对神经认知下降和神经功能等终点的影响仍需更多数据支持。
关键数值与推荐
- PBT治疗脑膜瘤在特定但非routine病例中具有安全提升剂量的潜力。
- 低级别胶质瘤中PBT提升剂量的应用少于胶质母细胞瘤。
临床怎么用
- 脑膜瘤可考虑PBT以获得高长期局部控制和低症状恶化。
- 特定脑膜瘤病例可考虑PBT安全提升剂量,但非routine。
- 低级别胶质瘤可考虑PBT在不增加严重毒性下提升剂量并维持生活质量。
- 高级别胶质瘤再照射可考虑PBT或CIRT以潜在提高安全性。
局限性
- 现有研究多为回顾性,存在患者选择偏倚。
- 患者人群和治疗(包括光子/粒子混合治疗)存在异质性。
- 数据数量和质量有限,经济性问题仍存重大疑问。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rapid rise of particle therapy across the world necessitates evidence to justify its ever-increasing utilization. This narrative review summarizes the current status of these technologies on treatment of both meningiomas and gliomas, the most common benign and malignant primary brain tumors, respectively. Proton beam therapy (PBT) for meningiomas displays high rates of long-term local control, low rates of symptomatic deterioration, along with the potential for safe dose-escalation in select (but not necessarily routine) cases. PBT is also associated with low adverse events and maintenance of functional outcomes, which have implications for quality of life and cost-effectiveness measures going forward. Data on carbon ion radiation therapy (CIRT) are limited; existing series describe virtually no high-grade toxicities and high local control. Regarding the few available data on low-grade gliomas, PBT provides opportunities to dose-escalate while affording no increase of severe toxicities, along with maintaining appropriate quality of life. Although dose-escalation for low-grade disease has been less frequently performed than for glioblastoma, PBT and CIRT continue to be utilized for the latter, and also have potential for safer re-irradiation of high-grade gliomas. For both neoplasms, the impact of superior dosimetric profiles with endpoints such as neurocognitive decline and neurologic funcionality, are also discussed to the extent of requiring more data to support the utility of particle therapy. Caveats to these data are also described, such as the largely retrospective nature of the available studies, patient selection, and heterogeneity in patient population as well as treatment (including mixed photon/particle treatment). Nevertheless, multiple prospective trials (which may partially attenuate those concerns) are also discussed. In light of the low quantity and quality of available data, major questions remain regarding economic concerns as well.
引用
- Adeberg S, Harrabi SB, Verma V, et al. Treatment of meningioma and glioma with protons and carbon ions. Radiat Oncol. 2017. PMID: 29195506. doi:10.1186/s13014-017-0924-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。